Opportunity Information: Apply for RFA EH 11 001
Apply for RFA EH 11 001
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Program to Support New Implementation of State or Territorial Public Health Laboratory Capacity for Newborn Bloodspot Screening of Severe Combined Immune Deficiency (SCID)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.065 Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure.
- This funding opportunity was created on May 6, 2011 and posted on Mar 17, 2011.
- Applicants must submit their applications by May 31, 2011 Letter of Intent Due Date April 15, 2011 Application Due Date May 31, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $900,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Applicants Eligible Organizations Eligible applicants are State or Territorial Public Health Newborn Bloodspot Screening Programs. Eligible applicants may apply either as an individual organization, or as the lead member of a consortium of multiple State Public Health laboratories with an existing Newborn Bloodspot Screening program, or in partnership with an organization from the following list Public nonprofit organizations private nonprofit organizations for profit organizations small, minority, and women owned businesses universities colleges research institutions hospitals community based organizations faith based organizations federally recognized or state recognized American Indian/Alaska Native tribal governments American Indian/Alaska Native tribally designated organizations Alaska Native health corporations urban Indian health organizations tribal epidemiology centers state and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) and political subdivisions of states (in consultation with states). A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov. Non domestic (non U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non U.S.) components of U.S. Organizations are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC grant opportunity (Funding Opportunity Number RFA EH 11 001) is a discretionary cooperative agreement designed to help states and U.S. territories launch newborn bloodspot screening for Severe Combined Immune Deficiency (SCID) for the first time. It is specifically aimed at public health newborn screening programs that were not fully operational for SCID screening before January 2011, with the overall intent of accelerating the adoption of SCID screening as a routine part of newborn screening practice and strengthening the infrastructure needed to run these tests reliably.
The program focuses on four main objectives. First, it seeks to expand laboratory capacity by covering capital and start-up costs tied directly to implementing SCID testing, such as purchasing laboratory equipment, supplies, and reagents needed to perform the screening. Second, it aims to grow the workforce by increasing the number of laboratory scientists who have the technical knowledge and hands-on skill to conduct SCID newborn screening within public health laboratory settings. Third, it supports training and outreach to the broader public health and clinical community, including laboratory staff, newborn screening program officials, healthcare providers, and primary care physicians, so that SCID screening is understood, used correctly, and integrated into standard newborn care. Fourth, it encourages participation in collaborations that improve how screening results are interpreted, including work on data analysis methods and statistical algorithms that can strengthen the predictive value of primary SCID screening tests and reduce avoidable false positives or unnecessary follow-up.
Funding is limited and framed as start-up support rather than long-term operational financing. The announcement emphasizes that awards are intended as seed funding, meaning applicants must show a clear commitment and plan to secure other funding sources to sustain routine SCID screening operations after the project period ends. In other words, the CDC support is meant to help programs get up and running and build capacity, but not to permanently underwrite ongoing testing.
The CDC expected to make two awards, with an estimated total program funding level of $900,000. The ceiling for a single award is $450,000, and there is no stated award floor. There is no cost-sharing or matching requirement. The activity is categorized under health, and the CFDA listing is 93.065 (Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure), which reflects the emphasis on laboratory readiness and workforce development rather than clinical service delivery alone.
Eligible applicants are State or Territorial Public Health Newborn Bloodspot Screening Programs. Programs may apply on their own, as the lead of a multi-state public health laboratory consortium, or in partnership with other organizations. The eligibility language allows partnerships with a broad range of entities (such as universities, hospitals, nonprofits, and certain tribal organizations), but the core applicant must be tied to an eligible state or territorial public health newborn screening program. The announcement also allows state and local governments and their Bona Fide Agents (including numerous U.S. jurisdictions and affiliated entities) to apply, provided that a bona fide agent submits the required legal, binding documentation from the state or local government confirming that status. Foreign organizations are not eligible, and foreign components of U.S. organizations are not permitted.
Key dates reflect a short application window in 2011. The opportunity was posted March 17, 2011, with a letter of intent due April 15, 2011. The original application deadline was May 16, 2011, later extended to May 31, 2011. The opportunity was archived June 15, 2011. The administering agency is the Centers for Disease Control and Prevention, and applicant support was provided through the CDC Procurement and Grants Office (PGOTIM@cdc.gov, 770-488-2700) for assistance accessing the full announcement.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is a CDC discretionary cooperative agreement (Funding Opportunity Number RFA EH 11 001) intended to help states and U.S. territories launch newborn bloodspot screening for Severe Combined Immune Deficiency (SCID) for the first time.
What is the main goal of the program?
The overall intent is to accelerate adoption of SCID screening as a routine part of newborn screening practice and to strengthen the infrastructure needed to run SCID tests reliably within public health newborn screening programs.
Who is this opportunity meant for?
It is specifically aimed at public health newborn screening programs that were not fully operational for SCID screening before January 2011.
What type of grant mechanism is being used?
The funding is provided as a discretionary cooperative agreement through the Centers for Disease Control and Prevention (CDC).
What are the major objectives of the program?
The program focuses on four main objectives: (1) expanding laboratory capacity for SCID screening start-up needs, (2) growing the laboratory workforce able to perform SCID screening, (3) supporting training and outreach so SCID screening is correctly understood and integrated into newborn care, and (4) encouraging participation in collaborations that improve interpretation of screening results (including data analysis methods and statistical algorithms) to strengthen predictive value and reduce avoidable false positives or unnecessary follow-up.
What kinds of costs are supported under the laboratory capacity objective?
The announcement describes support for capital and start-up costs tied directly to implementing SCID testing, including purchasing laboratory equipment and obtaining supplies and reagents needed to perform the screening.
Does this opportunity support hiring or building laboratory expertise?
Yes. One objective is to increase the number of laboratory scientists with the technical knowledge and hands-on skill needed to conduct SCID newborn screening in public health laboratory settings.
Who can be included in training and outreach activities?
Training and outreach may involve laboratory staff, newborn screening program officials, healthcare providers, and primary care physicians so SCID screening is understood, used correctly, and integrated into standard newborn care.
What does the collaboration and data analysis objective cover?
The opportunity encourages participation in collaborations that improve interpretation of screening results, including work on data analysis methods and statistical algorithms designed to strengthen the predictive value of primary SCID screening tests and reduce avoidable false positives or unnecessary follow-up.
Is the funding meant to cover long-term SCID screening operations?
No. Funding is described as limited and framed as start-up support (seed funding) rather than long-term operational financing. Applicants are expected to show a commitment and plan to secure other funding sources to sustain routine SCID screening after the project period ends.
How many awards did CDC expect to make?
CDC expected to make two awards.
What is the estimated total funding available under the program?
The estimated total program funding level is $900,000.
What is the maximum (ceiling) award amount?
The ceiling for a single award is $450,000.
Is there a minimum (floor) award amount?
No award floor is stated in the information provided.
Is cost sharing or matching required?
No. There is no cost-sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The CFDA listing is 93.065, titled "Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure."
What program area does this opportunity fall under?
The activity is categorized under health.
Who is eligible to apply?
Eligible applicants are State or Territorial Public Health Newborn Bloodspot Screening Programs.
Can a program apply as part of a multi-state effort?
Yes. Programs may apply on their own, as the lead of a multi-state public health laboratory consortium, or in partnership with other organizations.
Are partnerships with other organizations allowed?
Yes. The eligibility language allows partnerships with a broad range of entities (including universities, hospitals, nonprofits, and certain tribal organizations), but the core applicant must be tied to an eligible state or territorial public health newborn screening program.
Can state or local governments apply through a bona fide agent?
Yes. State and local governments and their Bona Fide Agents may apply, provided the bona fide agent submits required legal, binding documentation from the state or local government confirming that status.
Are foreign organizations eligible to apply?
No. Foreign organizations are not eligible.
Are foreign components of U.S. organizations allowed?
No. Foreign components of U.S. organizations are not permitted.
When was the opportunity posted?
The opportunity was posted on March 17, 2011.
Was a letter of intent required, and when was it due?
A letter of intent was due April 15, 2011.
What was the application deadline?
The original application deadline was May 16, 2011, and it was later extended to May 31, 2011.
Is this opportunity still open?
No. The opportunity was archived on June 15, 2011.
Which agency administers this funding opportunity?
The administering agency is the Centers for Disease Control and Prevention (CDC).
Who was the point of contact for applicant support?
Applicant support was provided through the CDC Procurement and Grants Office. The contact information listed was PGOTIM@cdc.gov and 770-488-2700 for assistance accessing the full announcement.
Browse more opportunities from the same category: Health
Next opportunity: Research and Development for Hydrogen Storage
Previous opportunity: Mill Creek Fish Passage Assessment and Restoration Project, Phase 1
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA EH 11 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA EH 11 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Instructions for Preparing an Interim Progress Report Apply for CDC RFA HM07 70205CONT11 Funding Number: CDC RFA HM07 70205CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Instructions for Preparing an Interim Progress Report Apply for CDC RFA HM07 70305CONT11 Funding Number: CDC RFA HM07 70305CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Improving Surveillance for Diseases of Public Health Significance for U.S. Bound Refugees and Other Mobile Populations Thailand Apply for CDC RFA CK11 1103 Funding Number: CDC RFA CK11 1103 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Study Implementation Cooperative Agreement (UM1) Apply for PAR 11 168 Funding Number: PAR 11 168 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Multi Center Clinical Study Implementation Planning Grants (U34) Apply for PAR 11 169 Funding Number: PAR 11 169 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Improving the Overseas Detection and Preventing the Importation of Communicable Diseases Among U.S. Bound Refugees Apply for CDC RFA CK11 1104 Funding Number: CDC RFA CK11 1104 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| National Training and Technical Assistance Cooperative Agreements (NCA) Apply for HRSA 11 023 Funding Number: HRSA 11 023 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National HIV Training and Technical Assistance Cooperative Agreement Apply for HRSA 11 068 Funding Number: HRSA 11 068 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Patient Protection and Affordable Care Act Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Building and Strengthening Epidemiology, Laboratory and Health Information Systems Capacity in State and Local Health Departments Apply for CDC RFA CI10 101202PPHF11 Funding Number: CDC RFA CI10 101202PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Patient Protection and Affordable Care Act (ACA), Emerging Infections Programs (EIP), Enhancing Epidemiology and Laboratory Capacity Apply for CDC RFA CI10 00302PPHF11 Funding Number: CDC RFA CI10 00302PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Affordable Care Act (ACA) Capacity Building Assistance to Strengthen Public Health Infrastructure and Performance Apply for CDC RFA HM08 8050401PPHF11 Funding Number: CDC RFA HM08 8050401PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Instructions for Preparing an Interim Progress Report State Vital Statistics Improvement Program Apply for CDC RFA SH07 70105CONT11 Funding Number: CDC RFA SH07 70105CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the Bangkok Metropolitan Administration (BMA) in the Kingdom of Thailand Apply for CDC RFA GH11 11111 Funding Number: CDC RFA GH11 11111 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Assessments And Surveys For Public Health Action In Post Earthquake Haiti Apply for RFA GH 11 007 Funding Number: RFA GH 11 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Public Health Training Center Apply for HRSA 11 142 Funding Number: HRSA 11 142 Agency: Health Resources and Services Administration Category: Health Funding Amount: $650,000 |
| Human Immunodeficiency Virus (HIV) Prevention Projects for Young Men of Color Who Have Sex with Men and Young Transgender Persons of Color Apply for CDC RFA PS11 1113 Funding Number: CDC RFA PS11 1113 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Public Prevention Health Fund Strengthening Public Health Infrastructure for Improved Health Outcomes AKA National Public Health Improvement Initiative Apply for CDC RFA CD10 101101PPHF11 Funding Number: CDC RFA CD10 101101PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,093,164 |
| Surveillance of Birth Defects in Low and Middle Income Countries Apply for CDC RFA DD11 1104 Funding Number: CDC RFA DD11 1104 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Engaging State/Local Emergency Management Agencies to Improve Apply for CDC RFA TP10 100402CONT11 Funding Number: CDC RFA TP10 100402CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NINDS Program Project Grant (P01) Apply for PAR 11 172 Funding Number: PAR 11 172 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA EH 11 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.